Project Grant SB1AG087756
Award Date
7/1/25
Completion Date
3/31/27
Dollars Obligated
$2M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of CMS121, an innovative drug candidate for the treatment of Alzheimer's disease (AD). The funding will support two key components: 1) A 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human subjects with mild to moderate AD, and 2) The...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...
This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
This federal Project Grant award from the National Institute on Aging (NIA), under CFDA 93.866 Aging Research, is providing $509,038 to Ceiba Bio Inc. to develop a blood-based exercise mimetic as a potential treatment for Alzheimer's disease and related dementias. The key objectives are to: 1) identify 3 lead recombinant human GPLD1 molecules, 2) establish optimal exposure through in vivo PK profiling in aged mice, and 3) test 1 primary and 1 alternate lead GPLD1 molecule for disease...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), is focused on developing a RUNX1 modulator to slow cognitive decline in Alzheimer's disease (AD). The $391,850 award, with a period of performance from June 15, 2025 to August 31, 2026, is funding Third Element Bio Inc. to: 1) conduct lead optimization of RUNX1-targeting antisense oligonucleotides (ASOs) to improve their safety and potency, and 2) demonstrate the...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This $1,041,646 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports the early clinical development of modified P8 (MP8), a novel peptide drug candidate for the treatment of Alzheimer's disease. The grant recipient, Cenna Biosciences Inc., aims to conduct activities to support a first-in-human clinical study of MP8, including chemistry, manufacturing, and controls (CMC) work, a pre-IND meeting with the FDA, IND application submission,...
The National Institute on Aging (NIA) awarded a $2,244,471 Project Grant under CFDA 93.866 (Aging Research) to Oregon Health & Science University (OHSU) to develop a first-in-class, CNS-penetrant small molecule agonist for G protein-coupled receptor 39 (GPR39) as a potential treatment for vascular cognitive impairment and dementia (VCID). The 3-year project from September 2023 to August 2026 will use in vitro and in vivo assays to identify lead compounds, determine their safety and...